Please enable Javascript
Kerri Fitzgerald
Articles by Kerri Fitzgerald
FDA Approves First Noncovalent BTK Inhibitor Pirtobrutinib for MCL
Kerri Fitzgerald
Mantle Cell Lymphoma
|
January 27, 2023
The FDA approved the first and only noncovalent BTK inhibitor for MCL.
Read More
Study Identifies Indicators of Improved Outcomes in Burkitt Lymphoma
Kerri Fitzgerald
Meeting News
|
December 21, 2022
Race/ethnicity, income, and access to chemotherapy and radiation therapy improved outcomes in patients with Burkitt lymphoma.
Read More
Real-World Study Suggests Cell of Origin in DLBCL May Impact Response to CAR-T Therapy
Kerri Fitzgerald
Meeting News
|
December 21, 2022
The cell of origin in patients with diffuse large B-cell lymphoma may impact their response to CAR-T therapy and survival.
Read More
CALR Mutation in Myelofibrosis Associated with Greater Risk of Anemia
Kerri Fitzgerald
Meeting News
|
December 19, 2022
Mutation of CALR in patients with myelofibrosis may be associated with a more anemic phenotype at diagnosis.
Read More
This Chemotherapy-Free Regimen Appears Effective for Ph-Positive ALL
Kerri Fitzgerald
Meeting News
|
December 19, 2022
Simultaneous treatment with ponatinib and blinatumomab was safe and effective in patients with newly diagnosed PH+ ALL.
Read More
First All-Oral Triplet Regimen for AML Looks Promising
Kerri Fitzgerald
Acute Myeloid Leukemia
|
December 19, 2022
The combination of decitabine/cedazuridine, venetoclax, and an IDH1 inhibitor was effective in treating IDH-mutated AML.
Read More
Study Assesses Clearance of Baseline Mutations Following Treatment with Ivosidenib and Azacitidine in AML
Kerri Fitzgerald
Meeting News
|
December 19, 2022
Ivosidenib and azacitidine led to deep and durable remissions associated with clearance of IDH1-mutated newly diagnosed AML.
Read More
Study Assesses Clinical Trial Recruitment Difficulties in a Lymphoma Cohort
Kerri Fitzgerald
Hodgkin Lymphoma
|
December 10, 2022
The REALYSA study has garnered an enrollment rate of 54%—higher than typical clinical trial inclusion rates.
Read More
Phase I Study Demonstrates Benefit of Combination Selinexor, Ruxolitinib for Treatment-Naïve Myelofibrosis
Kerri Fitzgerald
Myeloproliferative Neoplasms
|
December 10, 2022
Selinexor plus ruxolitinib demonstrated promising clinical activity in patients with treatment-naïve myelofibrosis.
Read More
Study Identifies Causes of Increased Risk of Myeloma in Black Americans
Kerri Fitzgerald
Myeloma
|
December 10, 2022
A new study presented at the 2022 ASH Annual Meeting identified causes of the increased myeloma risk in Black Americans.
Read More